BTS guidelines for the management of community acquired pneumonia in adults: update 2009
about
Antibiotics for community-acquired pneumonia in adult outpatientsEmpiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adultsShort-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatientsIncreasing burden of community-acquired pneumonia leading to hospitalisation, 1998-2014Severe community-acquired pneumonia: timely management measures in the first 24 hoursMethodological criticisms in the evaluation of Pneumococcal Conjugate Vaccine effectivenessAdjunctive Corticotherapy for Community Acquired Pneumonia: A Systematic Review and Meta-AnalysisAntibiotic Resistance in Streptococcus pneumoniae after Azithromycin Distribution for TrachomaViral-bacterial interactions-therapeutic implicationsDuration of antimicrobial therapy in community acquired pneumonia: less is moreCommunity-acquired pneumonia: identification and evaluation of nonrespondersPharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient PopulationsLung ultrasound: a promising tool to monitor ventilator-associated pneumonia in critically ill patientsSurveillance of antibiotic resistanceAccuracy of Lung Ultrasonography versus Chest Radiography for the Diagnosis of Adult Community-Acquired Pneumonia: Review of the Literature and Meta-AnalysisCeftobiprole medocaril in the treatment of hospital-acquired pneumoniaPneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitalsRisk factors for hospital admission in the 28 days following a community-acquired pneumonia diagnosis in older adults, and their contribution to increasing hospitalisation rates over time: a cohort studyPostviral Complications: Bacterial PneumoniaHealthcare-Associated Pneumonia Does Not Accurately Identify Potentially Resistant Pathogens: A Systematic Review and Meta-AnalysisFailure of CRP decline within three days of hospitalization is associated with poor prognosis of Community-acquired PneumoniaClinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults.Management of Legionella in the intensive care settingLimiting severe outcomes and impact on intensive care units of moderate-intermediate 2009 pandemic influenza: role of infectious diseases units.Severity of influenza A 2009 (H1N1) pneumonia is underestimated by routine prediction rules. Results from a prospective, population-based study.Approaching the quality of antibiotic prescriptions in primary care using reimbursement data.The association between benzodiazepines and influenza-like illness-related pneumonia and mortality: a survival analysis using UK Primary Care data.Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohortsDo influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health recordsPenicillin treatment for patients with Community-Acquired Pneumonia in Denmark: a retrospective cohort study.Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis.The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature reviewInitial use of one or two antibiotics for critically ill patients with community-acquired pneumonia: impact on survival and bacterial resistanceOral versus intravenous clarithromycin in moderate to severe community-acquired pneumonia: an observational studyDefining and predicting severe community-acquired pneumonia.Evaluation of Curetis Unyvero, a multiplex PCR-based testing system, for rapid detection of bacteria and antibiotic resistance and impact of the assay on management of severe nosocomial pneumonia.The management of community-acquired pneumonia in the elderlyAssociation between hospital case volume and mortality in non-elderly pneumonia patients stratified by severity: a retrospective cohort study.Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI).Novel aspects on the pathogenesis of Mycoplasma pneumoniae pneumonia and therapeutic implications
P2860
Q24193127-92195FFB-2FA6-42E1-B62E-47DFD16E3AECQ24200609-9AB82E92-B4B8-4103-8CFA-4A272EE7E475Q24235438-C01B5804-AFCE-4079-9A09-4BEEA39DFBC1Q24658576-E12C0EAE-79D0-4D53-A601-32C1D8A48E9CQ26738591-B6CB02E3-CB92-4081-A0C3-ED0E285BEE9EQ26770693-ABF76D9D-A73A-4FE7-A3DF-439DBC35352FQ26774000-899C04CD-C7FB-494B-817A-3B8B3C448E34Q26777935-587CC729-47AC-4FD6-AA26-7771B6F7168FQ26825261-C527F41D-E740-4F93-83FA-1D997E8C376DQ26828493-3CD07A74-DFB0-44E9-8C25-54C08353554CQ27002420-308AEC5E-76DB-4890-86E9-D65E3629EDCEQ28066877-1BE3BDC9-09C8-4C06-B4C2-959382BE6119Q28074609-EF12CA98-6CAE-4993-A88B-F87064CB1EEFQ28082571-57FF2546-457B-4A5D-BCFD-78F0084A01B3Q28084889-4DB7BA68-A663-4063-ABEF-599C7488C2D1Q28085517-EEAD7E1A-57ED-4F70-A360-2A21F905951AQ28587900-CFC5EB40-2C2A-4189-9052-976DE1AFF931Q28604186-B637DBF4-C784-4F96-BF79-F5B990E53E4DQ29248089-F4DE9A04-0AF5-48DC-9A0A-292DDC546B04Q29543747-AD5239DF-7983-4D05-8CD0-61CE60279B23Q30160730-66BB10F9-7D20-4043-8108-30ED986A78C7Q30398779-6B3DF6DF-75B3-40DD-AF06-B61DB253AA14Q30417993-C9ABEE33-274C-4BFB-991B-53D1FC74AA23Q30420451-795ED214-4EA8-4407-B0C2-EF9F3F0E4F52Q30422390-AB41754D-DB77-4089-8213-40BAA2BA64A6Q30566077-0A11278C-AC81-4E0F-8675-7F0A37E39ABEQ31100154-C70299FC-F60E-42FB-86FF-37C28F67F320Q31108856-985EB197-6B2E-4AA4-B4B2-35EC098ACACDQ33552701-D26CB2CC-9EEA-43B3-9EDB-E60FC853B412Q33581932-B41BAAA7-6342-4654-A42E-1C02249CE50EQ33586621-8106ABCF-2B84-4C4E-8865-01F453537A83Q33701151-C8AD447F-7460-46D4-A502-477E2669CDDDQ33749940-9C4DC2A4-CB0C-44AA-B871-7305213E0339Q33801782-B8459C51-2FFD-42CA-A5DB-69F1646C25E4Q33872274-34A12832-8F70-4022-86A7-06CB01B77B78Q33900108-B3F7580B-10A7-4237-A3E0-296B7F8F62A9Q33915736-EED5C849-33F1-488C-9FC0-50A6A32CB5FCQ33928093-48975E86-E443-4AFD-BF0B-03C95042469FQ33929402-2A7ECCAD-81EF-4110-A71F-E49DD3B30B75Q34023899-6C8FD78E-AD57-4231-A5BF-6997124ACA0A
P2860
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@ast
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@en
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@en-gb
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@nl
type
label
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@ast
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@en
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@en-gb
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@nl
prefLabel
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@ast
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@en
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@en-gb
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@nl
P2093
P3181
P356
P1433
P1476
BTS guidelines for the management of community acquired pneumonia in adults: update 2009
@en
P2093
C Jamieson
H J Roberts
I Le Jeune
J T Macfarlane
M A Woodhead
R C George
P304
iii1-iii55
P3181
P356
10.1136/THX.2009.121434
P407
P433
P577
2009-09-24T00:00:00Z